AIM
Price
$2.45
Change
-$0.09 (-3.54%)
Updated
Aug 29 closing price
Capitalization
6.64M
URGN
Price
$19.45
Change
+$0.21 (+1.09%)
Updated
Aug 29 closing price
Capitalization
899.84M
77 days until earnings call
Interact to see
Advertisement

AIM vs URGN

Header iconAIM vs URGN Comparison
Open Charts AIM vs URGNBanner chart's image
AIM ImmunoTech
Price$2.45
Change-$0.09 (-3.54%)
Volume$57.69K
Capitalization6.64M
UroGen Pharma
Price$19.45
Change+$0.21 (+1.09%)
Volume$1.29M
Capitalization899.84M
AIM vs URGN Comparison Chart in %
Loading...
AIM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AIM vs. URGN commentary
Sep 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AIM is a Hold and URGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 01, 2025
Stock price -- (AIM: $2.45 vs. URGN: $19.45)
Brand notoriety: AIM and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AIM: 28% vs. URGN: 102%
Market capitalization -- AIM: $6.64M vs. URGN: $899.84M
AIM [@Biotechnology] is valued at $6.64M. URGN’s [@Biotechnology] market capitalization is $899.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AIM’s FA Score shows that 1 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • AIM’s FA Score: 1 green, 4 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, both AIM and URGN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AIM’s TA Score shows that 4 TA indicator(s) are bullish while URGN’s TA Score has 3 bullish TA indicator(s).

  • AIM’s TA Score: 4 bullish, 5 bearish.
  • URGN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, AIM is a better buy in the short-term than URGN.

Price Growth

AIM (@Biotechnology) experienced а -9.26% price change this week, while URGN (@Biotechnology) price change was +0.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.70%. For the same industry, the average monthly price growth was +20.57%, and the average quarterly price growth was +29.45%.

Reported Earning Dates

URGN is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (-0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
URGN($900M) has a higher market cap than AIM($6.64M). URGN YTD gains are higher at: 82.629 vs. AIM (-87.626). AIM has higher annual earnings (EBITDA): -15.32M vs. URGN (-119.79M). URGN has more cash in the bank: 196M vs. AIM (835K). AIM has less debt than URGN: AIM (2.81M) vs URGN (125M). URGN has higher revenues than AIM: URGN (91.9M) vs AIM (121K).
AIMURGNAIM / URGN
Capitalization6.64M900M1%
EBITDA-15.32M-119.79M13%
Gain YTD-87.62682.629-106%
P/E RatioN/AN/A-
Revenue121K91.9M0%
Total Cash835K196M0%
Total Debt2.81M125M2%
FUNDAMENTALS RATINGS
AIM vs URGN: Fundamental Ratings
AIM
URGN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9734
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AIM's Valuation (33) in the null industry is somewhat better than the same rating for URGN (70) in the Biotechnology industry. This means that AIM’s stock grew somewhat faster than URGN’s over the last 12 months.

AIM's Profit vs Risk Rating (100) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that AIM’s stock grew similarly to URGN’s over the last 12 months.

AIM's SMR Rating (100) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that AIM’s stock grew similarly to URGN’s over the last 12 months.

URGN's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for AIM (97) in the null industry. This means that URGN’s stock grew somewhat faster than AIM’s over the last 12 months.

URGN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as AIM (100) in the null industry. This means that URGN’s stock grew similarly to AIM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AIMURGN
RSI
ODDS (%)
Bullish Trend 6 days ago
75%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
83%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
86%
MACD
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
80%
Advances
ODDS (%)
Bullish Trend 11 days ago
77%
Bullish Trend 6 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 6 days ago
74%
N/A
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
AIM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSQCX9.70-0.02
-0.21%
Calvert Global Small-Cap Equity C
DQIAX34.21-0.19
-0.55%
BNY Mellon Equity Income Fund A
RVPIX8.95-0.07
-0.78%
Royce Smaller-Companies Growth Instl
LMGRX69.46-0.60
-0.86%
ClearBridge International Growth R
PSGIX23.10-0.20
-0.86%
BlackRock Advantage Small Cap Gr Instl